LIFE SCIENCES PENNSYLVANIA

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive. H.R.5100 INNOVATE Act.

Client expense: — · Firm income: —

Matched citations: H.R.5100

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: HR 5343

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: S1717

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Client expense: — · Firm income: —

Matched citations: S.932

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive. H.R.5100 INNOVATE Act.

Client expense: — · Firm income: —

Matched citations: H.R.5100

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: HR 5343

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: S1717

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Client expense: — · Firm income: —

Matched citations: S.932

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive. H.R.5100 INNOVATE Act.

Client expense: — · Firm income: —

Matched citations: H.R.5100

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: HR 5343

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: S1717

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Client expense: — · Firm income: —

Matched citations: S.932

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive. H.R.5100 INNOVATE Act.

Client expense: $6,000 · Firm income: —

Matched citations: H.R.5100

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: $6,000 · Firm income: —

Matched citations: HR 5343

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: $6,000 · Firm income: —

Matched citations: S1717

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Client expense: $6,000 · Firm income: —

Matched citations: S.932

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025. Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive. H.R.5100 INNOVATE Act.

Client expense: — · Firm income: —

Matched citations: H.R.5100

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: HR 5343

As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access. Ensuring Patient Access to Critical Breakthrough Products Act (HR 5343/S1717). This legislation provides Medicare coverage for medical devices approved through the FDAs Breakthrough Devices Program. Without this legislation, devices receiving the Breakthrough Device designation and approval must often wait upwards of two to three years for payment codes from the Centers for Medicare and Medicaid Services. Without this legislation, patients in Medicare face coverage and reimbursement delays in access to life-changing innovations.

Client expense: — · Firm income: —

Matched citations: S1717

Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.The Rare Pediatric Disease Priority Review Voucher Program (PPRV) incentivizes the development of novel therapies to treat rare pediatric diseases. This program was not reauthorized by the end of 2024 and has therefore expired. The reauthorization of this vital program would be extended to September 30, 2029. The full US House of Representatives has not yet voted on this legislation. The Senate version of Give Kids a Chance Act of 2025 (S.932) was introduced in March and is awaiting any movement from the Senate HELP Committee.

Client expense: — · Firm income: —

Matched citations: S.932

Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Client expense: — · Firm income: —

Matched citations: HR 1691